Wells Fargo Starts Axsome Therapeutics (AXSM) at Overweight

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ORCL
2. SPY
3. SPCX
4. USO
5. CHWY
6. NAVN
7. HUMA
8. NVDA
9. CRWV
10. CME

September 3, 2024 5:06 AM UTC
Get Alerts AXSM Hot Sheet
Price: $162.33 +0.54%

Rating Summary:
    25 Buy, 1 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Join SI Premium – FREE
(Updated - September 3, 2024 6:35 AM EDT)

Wells Fargo initiates coverage on Axsome Therapeutics (NASDAQ: AXSM) with a Overweight rating and a price target of $140.00.

The analyst comments "Our 12-month price target of $140/sh is based on DCF analysis, using an 11% discount rate that accounts for the inherent risks of early-stage drug development and higher costs of capital relative to large-cap companies. We assume a -5% terminal growth rate as several products start to lose exclusivity from 2038 on."

For an analyst ratings summary and ratings history on Axsome Therapeutics click here. For more ratings news on Axsome Therapeutics click here.

Shares of Axsome Therapeutics closed at $88.86 yesterday.


You May Also Be Interested In





Related Categories

Analyst Comments, New Coverage

Related Entities

Wells Fargo, Maynard Um, Mark Zuckerberg, ARK